Literature DB >> 27549170

The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.

Melanie R Neeland1, Wei Shi1, Catherine Collignon2, Nadine Taubenheim1, Els N T Meeusen1, Arnaud M Didierlaurent2, Michael J de Veer3.   

Abstract

The liposome-based adjuvant AS01 incorporates two immune stimulants, 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21. AS01 is under investigation for use in several vaccines in clinical development. i.m. injection of AS01 enhances immune cell activation and dendritic cell (DC) Ag presentation in the local muscle-draining lymph node. However, cellular and Ag trafficking in the lymphatic vessels that connect an i.m. injection site with the local lymph node has not been investigated. The objectives of this study were: 1) to quantify the in vivo cellular immune response induced by AS01 in an outbred ovine model, 2) to develop a lymphatic cannulation model that directly collects lymphatic fluid draining the muscle, and 3) to investigate the function of immune cells entering and exiting the lymphatic compartments after s.c. or i.m. vaccination with AS01 administered with hepatitis B surface Ag (HBsAg). We show that HBsAg-AS01 induces a distinct immunogenic cellular signature within the blood and draining lymphatics following both immunization routes. We reveal that MHCII(high) migratory DCs, neutrophils, and monocytes can acquire Ag within muscle and s.c. afferent lymph, and that HBsAg-AS01 uniquely induces the selective migration of Ag-positive neutrophils, monocytes, and an MHCII(high) DC-like cell type out of the lymph node via the efferent lymphatics that may enhance Ag-specific immunity. We report the characterization of the immune response in the lymphatic network after i.m. and s.c. injection of a clinically relevant vaccine, all in real time using a dose and volume comparable with that administered in humans.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27549170     DOI: 10.4049/jimmunol.1600817

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines.

Authors:  Danielle M Valcourt; Chintan H Kapadia; Mackenzie A Scully; Megan N Dang; Emily S Day
Journal:  Adv Healthc Mater       Date:  2020-05-04       Impact factor: 9.933

2.  The adjuvant system AS01 up-regulates neutrophil CD14 expression and neutrophil-associated antigen transport in the local lymphatic network.

Authors:  M R Neeland; W Shi; C Collignon; E N T Meeusen; A M Didierlaurent; M J de Veer
Journal:  Clin Exp Immunol       Date:  2018-01-23       Impact factor: 4.330

3.  A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity.

Authors:  Murillo Silva; Yu Kato; Mariane B Melo; Ivy Phung; Brian L Freeman; Zhongming Li; Kangsan Roh; Jan W Van Wijnbergen; Hannah Watkins; Chiamaka A Enemuo; Brittany L Hartwell; Jason Y H Chang; Shuhao Xiao; Kristen A Rodrigues; Kimberly M Cirelli; Na Li; Sonya Haupt; Aereas Aung; Benjamin Cossette; Wuhbet Abraham; Swati Kataria; Raiza Bastidas; Jinal Bhiman; Caitlyn Linde; Nathaniel I Bloom; Bettina Groschel; Erik Georgeson; Nicole Phelps; Ayush Thomas; Julia Bals; Diane G Carnathan; Daniel Lingwood; Dennis R Burton; Galit Alter; Timothy P Padera; Angela M Belcher; William R Schief; Guido Silvestri; Ruth M Ruprecht; Shane Crotty; Darrell J Irvine
Journal:  Sci Immunol       Date:  2021-12-03

4.  Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity.

Authors:  Sebastian Ols; Lifei Yang; Elizabeth A Thompson; Pradeepa Pushparaj; Karen Tran; Frank Liang; Ang Lin; Bengt Eriksson; Gunilla B Karlsson Hedestam; Richard T Wyatt; Karin Loré
Journal:  Cell Rep       Date:  2020-03-24       Impact factor: 9.423

Review 5.  Development of New Preventive and Therapeutic Vaccines for Tuberculosis.

Authors:  Bo-Eun Kwon; Jae-Hee Ahn; Seunghwan Min; Hyeongseop Kim; Jungheun Seo; Sang-Gu Yeo; Hyun-Jeong Ko
Journal:  Immune Netw       Date:  2018-04-03       Impact factor: 6.303

Review 6.  Lymphatic Migration of Immune Cells.

Authors:  Henry R Hampton; Tatyana Chtanova
Journal:  Front Immunol       Date:  2019-05-28       Impact factor: 7.561

7.  Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-Action.

Authors:  Paul R Buckley; Kieran Alden; Margherita Coccia; Aurélie Chalon; Catherine Collignon; Stéphane T Temmerman; Arnaud M Didierlaurent; Robbert van der Most; Jon Timmis; Claus A Andersen; Mark C Coles
Journal:  Front Immunol       Date:  2019-09-12       Impact factor: 7.561

8.  Neutrophil Cells Are Essential for The Efficacy of a Therapeutic Vaccine against Paracoccidioidomycosis.

Authors:  Lucas Dos Santos Dias; Leandro B R Silva; Joshua D Nosanchuk; Carlos Pelleschi Taborda
Journal:  J Fungi (Basel)       Date:  2021-05-26

9.  Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.

Authors:  Wivine Burny; Andrea Callegaro; Viviane Bechtold; Frédéric Clement; Sophie Delhaye; Laurence Fissette; Michel Janssens; Geert Leroux-Roels; Arnaud Marchant; Robert A van den Berg; Nathalie Garçon; Robbert van der Most; Arnaud M Didierlaurent
Journal:  Front Immunol       Date:  2017-08-14       Impact factor: 7.561

10.  Aminated nanomicelles as a designer vaccine adjuvant to trigger inflammasomes and multiple arms of the innate immune response in lymph nodes.

Authors:  Chanyoung Song; Hathaichanok Phuengkham; Sun-Young Kim; Min Sang Lee; Ji Hoon Jeong; Sung Jae Shin; Yong Taik Lim
Journal:  Int J Nanomedicine       Date:  2017-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.